OptimizeRx Corporation Third Quarter 2026 Conference Call - OPTIMIZERX CORP

Financial Performance:

• Q3 2026 revenue was $21.6 million, a 17% year-over-year decrease from $26.1 million, driven by reduced spending from large customers and budget delays.
• Adjusted EBITDA reached $6.3 million, exceeding consensus and representing a margin improvement to ~29% (up from 20% in Q3 2025).
• Non-GAAP net income was $3.8 million ($0.20 per share), compared to $3.1 million ($0.16 per share) in the prior year.
• Gross margins remain strong in the low 70% range for the full year due to a favorable product mix and reduced lower-margin managed services.
• Operating cash flow for the first nine months was $12.9 million; ending cash balance stood at $22.3 million.
• Debt reduction continues ahead of schedule; the $13.4 million balance at quarter-end decreased to $10.4 million post-quarter, with additional principal repayments made.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance lowered to $87 million–$93 million (previously higher) due to contracted revenue tracking ~20% below prior year levels.
• Full-year 2026 Adjusted EBITDA guidance maintained at $21 million–$25 million, supported by cost management and margin strength.
• 2027 outlook is positive; contracted revenue for 2027 is tracking approximately 20% higher than the prior year.
• Management anticipates 2027 growth rates to align more closely with 2025 levels as the market recovers and a previously displaced top client returns.
• Q4 is expected to be critical for converting pent-up demand and securing revenue to meet the revised full-year targets.

Business Segments and Product Lines:

• Programmatic Distribution: Established partnerships with three major demand-side platforms (DeepIntent, The Trade Desk, PulsePoint) to integrate point-of-care inventory into broader omni-channel strategies; expanding inventory access to over 1.1 million verified HCPs.
• AI Capabilities: Launched enhancements to the Natural Language Audience Builder (NLAB) to include privacy-safe direct-to-consumer audiences, enabling unified HCP and consumer targeting.
• New Product Launches: Introduced COPEQ solution and DAP technology to support audience intelligence and media planning.
• Client Mix: Securing new business from mid-tier and long-tail pharmaceuticals and expanding into medtech; one displaced top-five client has returned, though spending remains below historical levels.

Market and Competitive Landscape:

• The pharmaceutical marketing environment is characterized by budget scrutiny, evolving spending priorities, and uncertainty regarding drug pricing policies (e.g., MFN pricing).
• OptimizeRx differentiates itself as the only tech company with a proprietary AI-enabled operating system integrated into a network of over 450 EHR and e-prescribing systems.
• The company sees a shift toward programmatic healthcare advertising, moving away from traditional direct sales to scalable distribution infrastructure.
• Competition remains high, but proprietary data, patented AI capabilities, and authenticated clinical inventory create significant barriers to entry.

Risks and Challenges:

• Customer Concentration: A limited number of large customers accounted for the revenue decline, specifically the temporary pullback from one major client representing ~10% of NRR.
• Revenue Recognition Timing: High dependency on Q4 execution to recognize contracted revenue; delayed buying cycles and lack of visibility into "buy-up" spending pose risks to hitting guidance.
• Regulatory Environment: Uncertainty surrounding government regulation, drug pricing policies (e.g., changes in Congress), and their impact on pharma marketing budgets.
• Net Revenue Retention (NRR): NRR dipped to 83% due to the large client's pullback, though management expects normalization in 2027.

Management Commentary and Tone:

• Tone was cautiously optimistic; management emphasized strong profitability and operational leverage despite top-line headwinds.
• Leadership highlighted a "renewed culture" and strengthened commercial organization, including the appointment of a new CMO.
• CFO Ed Stelmach concluded his tenure after the call; Andy DeSilva and Heather Favazza will assume CFO and Chief Accounting Officer roles respectively in January 2027.
• Management reiterated that the guidance reduction reflects near-term timing rather than a long-term shift in market opportunity.

Analyst Questions and Answers:

• Programmatic Runway: Management confirmed the three DSP partnerships represent 60–70% of the volume in the programmatic space, with early results showing encouraging bidding and volume.
• Mid/Long Tail Growth: Strong growth observed in mid-tier and long-tail clients, with one mid-tier client moving into the top 10 pool; growth in this segment is described as "very encouraging" and double-digit.
• NRR Trajectory: Analysts asked if 83% NRR was a trough; management indicated NRR should improve in 2027 as the major client's spending normalizes.
• Debt vs. Buybacks: Management confirmed a shift in strategy to prioritize debt reduction but indicated increased share repurchase activity is expected in Q4.
• Q4 Revenue Mix: Approximately 90% of the revised full-year guidance is contracted, with the remainder dependent on Q4 buy-up activity.

Other Key Points:

• The company operates as a "tech company" with a proprietary EHR network, distinguishing it from traditional marketing agencies.
• AI and data capabilities (DAP, NLAB) are foundational to the strategy, aiming to eliminate barriers between traditional direct sales and programmatic advertising.
• The company has successfully reduced operating expenses by $5.1 million year-over-year despite some severance costs.
• Management expects the "use it or lose it" nature of pharma marketing budgets to drive Q4 spending recovery as the year ends.